$80K — $100K *
We are seeking an experienced, highly motivated In Vivo Pharmacologist to join our team at Kymera Therapeutics. The successful candidate will support Kymera’s ongoing projects, by evaluating and analyzing novel therapies in vivo. This individual will create protocols, generate, and execute in vivo models to test the effectiveness of Kymera’s potential therapeutics in vivo.
Kymera Therapeutics is a biotechnology company pioneering a transformational new modality called targeted protein degradation (TPD), leveraging the body’s own protein recycling machinery, the Ubiquitin Proteasome System (UPS), to degrade disease-causing proteins and pursue disease targets long considered undruggable. Using our proprietary Pegasus drug development platform, we are discovering and developing novel, heterobifunctional molecules, that optimize the key elements of the UPS to deliver new oral therapies to address significant, unmet medical needs.
Kymera is rapidly advancing toward the clinic with our first program in immune-inflammatory disease slated to begin clinical studies in the first half of 2021 and additional programs in oncology indications entering the clinic in the second half of 2021. The company also continues to expand the reach of its protein degrader therapies through strategic partnerships with companies including Vertex Pharmaceuticals and most recently, Sanofi.
Kymera has recently designed new offices and lab space at the Arsenal Yards development in Watertown. We offer free parking and a free transportation shuttle from Harvard Square during commute hours.
Valid through: 12/1/2020